NeuroQuest Development Center, Inc.
Located in North Charleston, South Carolina, our development center is where the magic happens.
This wholly-owned subsidiary of NeuroQuest Ltd. is in charge of all research, fundraising, and business development.
We bring together experts from different fields to make our dream a reality:
A world where Alzheimer’s diagnosis doesn’t come with the fear of memory loss and cognitive decline.
About Us
NeuroQuest Ltd. is an Israeli biotechnology company founded in 2008 under the framework of the Israeli Chief Scientist’s Technology Incubators program and Trendlines Medical/Misgav Venture Accelerator. In 2013, the company established its US subsidiary, NeuroQuest Development Center, Inc., with the assistance and financial support of the South Carolina Research Authority (SCRA). Our primary focus is the optimization of our assay, NeuroScreen®, a novel, blood-based diagnostic tool for asymptomatic Alzheimer's Disease (AD). NeuroQuest Development Center is located in North Charleston, SC, but our team comprises experts from across the US and all around the world, with extensive experience in clinical trials, biostatistics, and business development.
Want to learn more about our team? Meet them here!
The problem that we are trying to solve is identifying asymptomatic AD individuals as early and effectively as possible. We have licensed the IP that protects valuable aspects of our technology from Yeda (the Weizmann Institute Technology Transfer Arm), acquiring an exclusive global license for the development and commercialization of NeuroScreen®. We previously collaborated with AIBL (the Australian Imaging, Biomarker, and Lifestyle) on a successful research project that included more than 500 individuals. Then, for our 2024 clinical study, we have partnered with Vikor Scientific LLC, a certified clinical laboratory in Charleston, SC, to reproduce our study results in a US lab, using frozen samples from the A-4 study. We strive to assess and improve our service constantly. That's why we are super excited for our upcoming fall 2025 validation study, meant to gather enough data to support our FDA application! The company has also applied for and is pending US and international patent approval for kits, methods, and compositions developed through our various clinical studies.
Our Vision
Positron emission tomography (PET) neuroimaging and cerebrospinal fluid (CSF) measurements have been the customary diagnostic methods for AD used by healthcare providers. These can yield an accurate diagnosis of AD even in asymptomatic patients. These methods, however, are invasive and expensive; therefore, they are mainly used for confirmatory diagnosis rather than for early detection.
Our vision is to present physicians with an easy-to-administer, blood-based biomarker test that can identify asymptomatic patients presenting with very low loads of Aβ42 in the brain (who are likely to progress to symptomatic AD).
Our solution is feasible and accessible, and will allow an earlier diagnosis of AD, a key factor in treatment success
01
Affordable, accessible, and immediate tool for AD screening
In 2023, the FDA approved the first two disease-modifying therapies that can reduce Aβ load in the brain. Research strongly suggests that these drugs appear to be more effective the earlier they are introduced to the patient, with maximal efficiency for individuals in the asymptomatic phase of AD. This means that patients need to be identified before damage starts to build up and become irreversible, leading to a chain reaction of decline.
To treat individuals before symptoms appear, our vision is to change the standard of care, establishing that everyone age 50+ needs to be regularly screened for AD. NeuroScreen® testing service will change the world by providing the best possible product at the lowest possible price, detecting the disease in millions of asymptomatic individuals with ease and efficiency.
02